Kalaris Therapeutics
Price & Volume
Stats
See moreOpen | $8.45 |
Previous Close | $8.33 |
Day Range | $7.82-$8.86 |
52W Range | $2.14-$12.90 |
Market Cap | $45.2M |
Shares Short | 399,288 |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$2.71 |
News
See moreYahoo Finance • 3 months ago
UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration
Yahoo Finance • 4 months ago
Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates
Yahoo Finance • 5 months ago
Piper Sandler assumes coverage of Kalaris stock with Neutral rating
Yahoo Finance • 5 months ago
Kalaris stock rating reiterated at Outperform by William Blair
About
CEO | Mr. Andrew Oxtoby |
CFO | Mr. Matthew Gall M.B.A. |
Address | 628 Middlefield Road, Palo Alto, CA, United States, 94301 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 14 |
